The Spanish National Court has applied the landmark ECJ dual pricing ruling to quash a decision by the Spanish Competition Commission dismissing a complaint against Pfizer's pricing policy for pharmaceutical products [1]. On 13 June 2011, the Spanish National Court («Audiencia Nacional« or «the Court«) quashed a non infringement decision by the Spanish Competition Commission (CNC) concerning the prices imposed to Spanish pharmaceutical wholesalers by Pfizer. The Court found that the CNC had been wrong to dismiss a complaint brought by the wholesaler Spain Pharma, against Pfizer's pricing policy. In its judgment, the Court relied on the landmark ruling by the Court of Justice of the European Union (ECJ) in the GSK dual pricing case [2]. The case was initiated in 2004 when
Share on
|
|
The Spanish National Court applies the ECJ "dual pricing" ruling to quash a decision by the Competition Authority concerning prices imposed to wholesalers by pharmaceutical company (Pfizer)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
